Current salvage therapies in Hodgkin lymphoma

Karan Chohan, Stephen M. Ansell

Research output: Contribution to journalReview articlepeer-review


Hodgkin lymphoma is a B-cell malignancy with approximately 85–95% complete remission rate following frontline therapy; however, relapsed/refractory disease occurs in roughly 10–30% of patients after treatment. Salvage therapy conventionally relies upon cytotoxic chemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation. A considerable number of patients experience relapse after transplantation, and further salvage management has included the use of allogeneic transplantation and radiotherapy. In the past decade, novel therapies including, brentuximab vedotin, PD-1 inhibitors, and the incorporation of PET-imaging into management have changed the paradigm of relapsed/refractory disease care. Novel therapies have been investigated in both single and combination regimens with other novel therapies and traditional chemotherapies. There is promising early work into the utility of CD30.CAR-T cell therapy, AFM13, camidanlumab tesirine, novel PD-1 inhibitors, and JAK1/JAK2 inhibition in management. Herein, we will review current salvage therapies in Hodgkin lymphoma and future directions in relapsed/refractory disease management.

Original languageEnglish (US)
Pages (from-to)1267-1280
Number of pages14
JournalLeukemia and Lymphoma
Issue number6
StatePublished - 2022


  • Hodgkin lymphoma
  • Salvage
  • relapsed/refractory

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Current salvage therapies in Hodgkin lymphoma'. Together they form a unique fingerprint.

Cite this